281 related articles for article (PubMed ID: 15898346)
1. Mitotane for adrenocortical carcinoma treatment.
Hahner S; Fassnacht M
Curr Opin Investig Drugs; 2005 Apr; 6(4):386-94. PubMed ID: 15898346
[TBL] [Abstract][Full Text] [Related]
2. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
3. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
4. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
6. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Luconi M; Mannelli M
Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
8. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
9. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
10. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
11. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
12. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.
Luton JP; Cerdas S; Billaud L; Thomas G; Guilhaume B; Bertagna X; Laudat MH; Louvel A; Chapuis Y; Blondeau P
N Engl J Med; 1990 Apr; 322(17):1195-201. PubMed ID: 2325710
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
16. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
Schteingart DE
N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
[No Abstract] [Full Text] [Related]
18. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR; Acco A; Bach C; Bonatto SJR; de Figueiredo BC; de Souza LM
Br J Clin Pharmacol; 2021 Jul; 87(7):2698-2710. PubMed ID: 33382119
[TBL] [Abstract][Full Text] [Related]
20. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]